Profile data is unavailable for this security.
About the company
Duopharma Biotech Berhad is a pharmaceutical company. The Company is engaged in the manufacture and distribution of pharmaceutical products. Its Consumer Healthcare (CHC) business is responsible for the marketing and distribution of over-the-counter products, including vitamins, minerals and supplements and cosmeceuticals in the domestic and regional markets. Its Ethical Classic Business is involved in the manufacture, distribution and sales of drugs that treat a wide range of ailments, from cardiovascular, dermatological and hormonal conditions to respiratory, sensory, nervous and musculoskeletal system diseases, among others. Its Ethical Specialty Business focuses on treatments, including generics and biosimilars-that target its three specialty (or franchise) areas, namely kidney disease, cancer and diabetes. It has core competencies in the pharmaceutical industry inclusive of manufacturing, research and development and commercialization and marketing of over 300 generic drugs.
- Revenue in MYR (TTM)748.03m
- Net income in MYR49.44m
- Incorporated2000
- Employees1.94k
- LocationDuopharma Biotech BhdLot 2599, Jalan Seruling 59, Kawasan 3,KLANG 41200MalaysiaMYS
- Phone+60 333232759
- Fax+60 333233923
- Websitehttps://duopharmabiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Golden Throat Holdings Group Co Ltd | 609.99m | 158.95m | 1.29bn | 860.00 | 8.09 | 1.65 | 7.05 | 2.11 | 0.3893 | 0.3893 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,270,917.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| IOL Chemicals and Pharmaceuticals Ltd. | 1.06bn | 60.60m | 1.29bn | 2.78k | 21.29 | -- | 13.65 | 1.22 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Natac Natural Ingredients SA | 214.42m | 41.30m | 1.30bn | 172.00 | 51.13 | 6.32 | 17.86 | 6.04 | 0.0124 | 0.0124 | 0.0742 | 0.1004 | 0.4869 | 0.1089 | 9.76 | 315,106.60 | 9.51 | -- | 11.90 | -- | 98.12 | -- | 19.53 | -- | 0.44 | -- | 0.5921 | -- | 3,152.85 | -- | 308.68 | -- | -- | -- |
| Duopharma Biotech Bhd | 748.03m | 49.44m | 1.33bn | 1.94k | 26.85 | 1.91 | 13.79 | 1.77 | 0.0514 | 0.0514 | 0.7776 | 0.7214 | 0.5771 | 1.99 | 3.69 | 385,581.40 | 3.81 | 5.54 | 4.62 | 6.91 | 35.98 | 39.77 | 6.61 | 9.49 | 2.93 | 4.03 | 0.4302 | 50.09 | 1.15 | 7.16 | -24.91 | 2.02 | -15.67 | -5.76 |
| Hanshang Group Co Ltd | 796.70m | 13.04m | 1.34bn | 2.38k | 98.97 | 1.29 | -- | 1.68 | 0.0757 | 0.0757 | 4.46 | 5.83 | 0.3718 | 2.65 | 8.25 | 552,235.40 | 0.3729 | 2.00 | 0.6192 | 3.89 | 55.85 | 57.24 | 1.00 | 4.89 | 0.2774 | 1.84 | 0.3798 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| PharmaSGP Holding SE | 515.09m | 85.47m | 1.34bn | 93.00 | 15.67 | 8.75 | 10.35 | 2.60 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
| Flerie AB | 41.30k | -78.62m | 1.35bn | 7.00 | -- | 0.0075 | -- | 32,787.89 | -102.92 | -102.92 | 0.0333 | 5,610.13 | 0.00004 | -- | -- | 14,285.71 | -7.86 | -37.64 | -7.99 | -41.14 | -126,944.00 | -450.51 | -190,353.00 | -454.62 | -- | -- | 0.0003 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Alliance Pharma plc | 1.03bn | -188.20m | 1.36bn | 290.00 | -- | 1.09 | -- | 1.33 | -0.0622 | -0.0622 | 0.3378 | 0.4124 | 0.4016 | 2.72 | 4.67 | 627,215.80 | -7.36 | -0.5982 | -8.08 | -0.6566 | 59.42 | 62.45 | -18.34 | -1.80 | 2.06 | 4.45 | 0.3218 | -- | 7.92 | 8.86 | -56.24 | -- | -25.01 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Permodalan Nasional Bhd.as of 29 Mar 2024 | 65.01m | 6.76% |
| Lembaga Tabung Hajias of 29 Mar 2024 | 38.50m | 4.00% |
| Eastspring Investments Bhd.as of 29 Mar 2024 | 13.18m | 1.37% |
| Public Mutual Bhd.as of 29 Mar 2024 | 10.23m | 1.06% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 9.56m | 0.99% |
| Hong Leong Assurance Bhd.as of 29 Mar 2024 | 8.50m | 0.88% |
| Eastspring Investments (Singapore) Ltd.as of 29 Mar 2024 | 7.71m | 0.80% |
| Manulife Investment Management (M) Bhd.as of 29 Mar 2024 | 6.10m | 0.63% |
| Great Eastern Life Assurance Co. Ltd.as of 29 Mar 2024 | 5.88m | 0.61% |
| AmanahRaya Investment Management Sdn. Bhd.as of 29 Mar 2024 | 4.96m | 0.52% |
